JP2025512749A5 - - Google Patents

Info

Publication number
JP2025512749A5
JP2025512749A5 JP2024554877A JP2024554877A JP2025512749A5 JP 2025512749 A5 JP2025512749 A5 JP 2025512749A5 JP 2024554877 A JP2024554877 A JP 2024554877A JP 2024554877 A JP2024554877 A JP 2024554877A JP 2025512749 A5 JP2025512749 A5 JP 2025512749A5
Authority
JP
Japan
Prior art keywords
peptide
amino acid
acid residues
amino acids
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512749A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/056642 external-priority patent/WO2023175022A1/en
Publication of JP2025512749A publication Critical patent/JP2025512749A/ja
Publication of JP2025512749A5 publication Critical patent/JP2025512749A5/ja
Pending legal-status Critical Current

Links

JP2024554877A 2022-03-16 2023-03-15 感染症の新しい治療法 Pending JP2025512749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305312 2022-03-16
EP22305312.5 2022-03-16
PCT/EP2023/056642 WO2023175022A1 (en) 2022-03-16 2023-03-15 New method to treat infectious diseases

Publications (2)

Publication Number Publication Date
JP2025512749A JP2025512749A (ja) 2025-04-22
JP2025512749A5 true JP2025512749A5 (cg-RX-API-DMAC10.html) 2026-03-13

Family

ID=81324956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554877A Pending JP2025512749A (ja) 2022-03-16 2023-03-15 感染症の新しい治療法

Country Status (6)

Country Link
US (1) US20250163116A1 (cg-RX-API-DMAC10.html)
EP (1) EP4493590A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025512749A (cg-RX-API-DMAC10.html)
KR (1) KR20240159852A (cg-RX-API-DMAC10.html)
CN (1) CN119053620A (cg-RX-API-DMAC10.html)
WO (1) WO2023175022A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023219197A1 (en) * 2022-02-14 2024-08-22 Sumant Singh CHUGH Methods of treating a cytokine storm related disease with recombinant mutated human angiopoietin-like 4
WO2025247922A1 (en) * 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating sepsis capillary leak syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6569645B2 (en) 1999-05-14 2003-05-27 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6579520B2 (en) 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
FR2827866B1 (fr) 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
WO2004011595A2 (fr) 2002-07-26 2004-02-05 Institut Pasteur Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
EP2513064B1 (en) 2009-12-17 2018-07-04 Katholieke Universiteit Leuven K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
TW201613977A (en) * 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201790336A1 (ru) * 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
WO2017180587A2 (en) * 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems

Similar Documents

Publication Publication Date Title
FI4211231T3 (fi) Peptidimodifioitu aav-kapsidi
Tang Specificity of pepsin and its dependence on a possible ‘hydrophobic binding site’
JP2023544683A5 (cg-RX-API-DMAC10.html)
Narita et al. The amino acid sequence of cardiotoxin from Formosan cobra (Naja naja atra) venom
CN109641034A (zh) 聚乙二醇化的猪干扰素及其使用方法
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
JP2008536483A5 (cg-RX-API-DMAC10.html)
JP2001520238A5 (cg-RX-API-DMAC10.html)
JP2021520818A5 (cg-RX-API-DMAC10.html)
CN110563802B (zh) 一组含n-甲基化氨基酸及n端脂肪酸修饰的抗菌肽类似物及其合成方法和应用
WO2015161820A1 (zh) 两亲性合成抗菌肽、其药物组合物及其用途
CN116178506B (zh) 一种订书肽及其用途
WO2002020561A1 (en) Novel polypeptides and anti-hiv drugs containing the same
JP2854970B2 (ja) マガイニンペプチドの置換アナログ
CA1337407C (en) Dimeric peptides having a stimulatory effect on haemopoiesis and a process for their preparation
WO1992004374A1 (fr) Nouveau polypeptide et medicament anti-vih prepare a partir de ce polypeptide
US10597426B2 (en) Polypeptide compound and preparation method and use thereof
US20180244724A1 (en) Polypeptide compound and preparation method and use thereof
WO2000032629A2 (en) Antiviral peptides
CN108976298A (zh) 一种来源于凡纳滨对虾血蓝蛋白的抗WSSV肽LvHcS52及其应用
JP2021531246A5 (cg-RX-API-DMAC10.html)
JP2023544300A5 (cg-RX-API-DMAC10.html)
JPH04505162A (ja) 白血球エラスターゼとカテプシンgとを阻害するペプチド、dna、ベクター、宿主生物と取得の方法、並びにペプチドを含有する薬剤学的製剤
EP3392263A1 (en) Polypeptide compound, preparation method therefor and use thereof
JP2023501308A5 (cg-RX-API-DMAC10.html)